Literature DB >> 35864719

Attention to risk information in direct-to-consumer prescription drug print ads: An eye-tracking study.

Kathryn J Aikin1, Helen W Sullivan1, Andrew Caporaso2, Victoria Hoverman2, Ting Yan2, Douglas Williams2, Jennifer Crafts2.   

Abstract

PURPOSE: FDA regulations state print ads for prescription drugs must provide a true statement of information "in brief summary" describing "side effects, contraindications and effectiveness." To fulfill these requirements, these ads typically display risk information both as important safety information (ISI) on the "main" ad page with the product claims and on a separate "brief summary" page. The ISI can be lengthy and may repeat brief summary content.
METHODS: The authors tested two versions of the ISI (short versus long) and the presence or absence of a brief summary in direct-to-consumer prescription drug print ads for two medical conditions: overactive bladder (N = 181) and rheumatoid arthritis (N = 179). Attention was measured with eye-tracking and self-report methods. Risk retention and perceptions were self-reported.
RESULTS: Participants spent more time viewing ads with a long ISI or a brief summary and in some instances, recalled more risks. The combination of a long ISI and a brief summary did not increase or decrease attention to or retention of risk information.
CONCLUSION: A long ISI and a brief summary may perform similar functions.
© 2022 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

Entities:  

Keywords:  attention; direct-to-consumer advertising; eye-tracking; prescription drug; risk; self-report questionnaire

Year:  2022        PMID: 35864719     DOI: 10.1002/pds.5511

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.732


  1 in total

1.  Does price disclosure in pharmaceutical advertising result in price transparency? Evidence from a randomized experiment.

Authors:  Ilene L Hollin; Jennifer Gerard Ball
Journal:  Explor Res Clin Soc Pharm       Date:  2022-09-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.